Amy R Deipolyi1, A John Iafrate2, Andrew X Zhu3, Emel A Ergul1, Suvranu Ganguli1, Rahmi Oklu4. 1. Division of Interventional Radiology, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, 290 Gray/Bigelow, Boston, MA 02114. 2. Division of Molecular Pathology, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, 290 Gray/Bigelow, Boston, MA 02114. 3. Division of Hematology/Oncology, Center for Liver Cancer, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, 290 Gray/Bigelow, Boston, MA 02114. 4. Division of Interventional Radiology, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, 290 Gray/Bigelow, Boston, MA 02114.. Electronic address: roklu@mgh.harvard.edu.
Abstract
PURPOSE: To assess how intratumoral shunting relates to liver metastasis and to clinical outcome. MATERIALS AND METHODS: Lung shunt fraction (LSF) was calculated from macroaggregated albumin scan after transcatheter injection of radioactive particles in 62 patients with colorectal cancer and liver metastases evaluated for selective internal radiation therapy (SIRT) from May 2007 to August 2012. Assessment was performed of how LSF, liver tumor burden, and systemic chemotherapy relate to survival and the presence of lung metastases. LSF and tumor burden were also assessed in a subset of patients who underwent genetic profiling with SNaPshot analysis. RESULTS: Patients with higher LSF were more likely to have lung metastases and decreased survival, whereas tumor burden was not associated with these outcomes. Patients with genetic mutations had significantly higher LSF than patients with no mutations. Patients who received chemotherapy before SIRT and had low LSF had the longest survival after SIRT. CONCLUSIONS: LSF may be a more robust marker of metastasis than tumor size. Increased LSF secondary to vascular shunting within liver metastasis is an indicator of distant lesions and is associated with decreased survival after SIRT. Intratumoral shunting may provide a conduit for circulating tumor cells to access more remote organs, bypassing filtration by liver parenchyma, and may be an important factor in metastasis from colorectal cancer.
PURPOSE: To assess how intratumoral shunting relates to liver metastasis and to clinical outcome. MATERIALS AND METHODS: Lung shunt fraction (LSF) was calculated from macroaggregated albumin scan after transcatheter injection of radioactive particles in 62 patients with colorectal cancer and liver metastases evaluated for selective internal radiation therapy (SIRT) from May 2007 to August 2012. Assessment was performed of how LSF, liver tumor burden, and systemic chemotherapy relate to survival and the presence of lung metastases. LSF and tumor burden were also assessed in a subset of patients who underwent genetic profiling with SNaPshot analysis. RESULTS:Patients with higher LSF were more likely to have lung metastases and decreased survival, whereas tumor burden was not associated with these outcomes. Patients with genetic mutations had significantly higher LSF than patients with no mutations. Patients who received chemotherapy before SIRT and had low LSF had the longest survival after SIRT. CONCLUSIONS: LSF may be a more robust marker of metastasis than tumor size. Increased LSF secondary to vascular shunting within liver metastasis is an indicator of distant lesions and is associated with decreased survival after SIRT. Intratumoral shunting may provide a conduit for circulating tumor cells to access more remote organs, bypassing filtration by liver parenchyma, and may be an important factor in metastasis from colorectal cancer.
Authors: Axel R Pries; Michael Höpfner; Ferdinand le Noble; Mark W Dewhirst; Timothy W Secomb Journal: Nat Rev Cancer Date: 2010-07-15 Impact factor: 60.716
Authors: Dora Dias-Santagata; Sara Akhavanfard; Serena S David; Kathy Vernovsky; Georgiana Kuhlmann; Susan L Boisvert; Hannah Stubbs; Ultan McDermott; Jeffrey Settleman; Eunice L Kwak; Jeffrey W Clark; Steven J Isakoff; Lecia V Sequist; Jeffrey A Engelman; Thomas J Lynch; Daniel A Haber; David N Louis; Leif W Ellisen; Darrell R Borger; A John Iafrate Journal: EMBO Mol Med Date: 2010-05 Impact factor: 12.137
Authors: Jingjie Hu; Hassan Albadawi; Brian W Chong; Amy R Deipolyi; Rahul A Sheth; Ali Khademhosseini; Rahmi Oklu Journal: Adv Mater Date: 2019-06-06 Impact factor: 30.849
Authors: Kazim H Narsinh; Mark Van Buskirk; Andrew S Kennedy; Mohammed Suhail; Naif Alsaikhan; Carl K Hoh; Kenneth Thurston; Jeet Minocha; David S Ball; Steven J Cohen; Michael Cohn; Douglas M Coldwell; Alain Drooz; Eduardo Ehrenwald; Samir Kanani; Charles W Nutting; Fred M Moeslein; Michael A Savin; Sabine Schirm; Samuel G Putnam; Navesh K Sharma; Eric A Wang; Steven C Rose Journal: Radiology Date: 2016-07-19 Impact factor: 11.105
Authors: Mohammad Elsayed; Bernard Cheng; Minzhi Xing; Ila Sethi; David Brandon; David M Schuster; Zachary Bercu; James Galt; Bruce Barron; Nima Kokabi Journal: Cardiovasc Intervent Radiol Date: 2020-10-01 Impact factor: 2.740